Vinorelbine emulsion - Mast Therapeutics

Drug Profile

Vinorelbine emulsion - Mast Therapeutics

Alternative Names: ANX-530; Exelbine; SDP-012; Vinorelbine injectable emulsion

Latest Information Update: 10 Jul 2014

Price : $50

At a glance

  • Originator SD Pharmaceuticals
  • Developer ADVENTRX Pharmaceuticals
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Highest Development Phases

  • Discontinued Breast cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2014 Vinorelbine emulsion - Mast Therapeutics is available for licensing as of 26 Mar 2014. http://www.masttherapeutics.com
  • 11 Mar 2013 ADVENTRX is now called Mast Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top